All News

dental,periodontal

Periodontal Mucosal Breaks Trigger RA Disease Activity

d Jack Cush, MD

Periodontal disease (PD) is more common in rheumatoid arthritis (RA), especially those with anti-citrullinated protein antibodies (ACPAs).  RA activity has been linked to the severity of PD and mucosal inflammation.

Read Article
lumbar,spine,lbp,pain

Which Meds are Best for Acute Low Back Pain?

d EurekAlert!

Acute low back pain (LBP) is a common cause of disability. An analysis in the Journal of Orthopaedic Research examined which non-opioid drugs are best for treating this condition.

Read Article
cost.price_.biologic.injectable.jpg

New Drug Formulations – For Patients or Profits?

d Madelaine Feldman, MD

Wang et al., in a JAMA Network Research Letter, recently reviewed Medicaid expenditures on adalimumab (ADA), sold under the brand name HUMIRA®. They noted that the introduction of the citrate-free formulation cost an extra $4.4B to Medicaid between 2014 and 2021.

Read Article
heavy,metal,sword,knight

Heavy Metals and the Risk of Arthritis

d Jack Cush, MD

The etiology of arthritis was studied using US National Health and Nutrition Examination Survey (NHANES) data and suggested that elevated concentrations of trace elements (TE: Pb, Cd, and Cu) were associated with increased risk of arthritis.

Read Article
Overview of Juvenile idiopathic arthritis (JIA) assoc uveitis (JIA-U) seen in 10–15% ofJIA pts, higher risk w/ ANA+, oligo-JIA, f& onset ≤6 yrs age. Rx options: topical steroids, MTX, ADA, INFLX, RTX and TCZ (review of TCZ in JIA-U) https://t.co/DIccOVLrmR https://t.co/6QD6g6orkp

Links:

Dr. John Cush RheumNow ( View Tweet)
A retrospective study from a Taiwan health insurance claims data analysis looked at the association between Hashimoto's thyroiditis and lupus. https://t.co/159JNLY6tf https://t.co/JxR88a84MN

Links:

Dr. John Cush RheumNow ( View Tweet)
Chest Pain & Fever Lessons from the clinic, brought to you by https://t.co/4UQlqwujiR March 18 &19, 2023 - Dallas, TX https://t.co/k98wmxxG2k

Links:

Dr. John Cush RheumNow ( View Tweet)

Raynaud's Phenomenon: Now You See Me, Now You Don't Manmeet Kaur, MD, presents at RWCS 2023. https://t.co/VsRZmzycXH https://t.co/ysWaHABKoP

Links:

Dr. John Cush RheumNow ( View Tweet)
Heavy Metals and the Risk of Arthritis The etiology of arthritis was studied using US NHANES data and suggested that elevated concentrations of trace elements (TE: Pb, Cd, and Cu) were associated with increased risk of arthritis. https://t.co/z8bzOorqTz https://t.co/u5cQqXDId2

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a chance to listen to last week's podcast? Check out our sneak peek and see what Dr. Cush finds surprising. https://t.co/zQIyVWwA8k https://t.co/I3PEUGUx2L

Links:

Dr. John Cush RheumNow ( View Tweet)
Survey of 300 Rheums, GI, Derms - concerns w/ new biosimilars - majority say economics arent favorable to switch to biosimilar - Yet majority "very to somewhat” comfortable w/ biosimilars - US: Slow biosimilar uptake due to disappointing costs https://t.co/6dUR4gA3I5 https://t.co/2bLzE70h6y

Links:

Dr. John Cush RheumNow ( View Tweet)
Im not sure this was necessary but - a metanalysis of 10 RCTs w/ 847 OA patients shows colchicine use in osteoarthritis had no efficacy as far as pain reduction (vs control; SMD= 0.17) & no improvement in function (SMD, - 0.37) https://t.co/67d1ouJyQR https://t.co/6xBJcQCYZt

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 25 studies, betw 1985 - 2021, showed US average annual visits for RA=5.25 for US rheums (vs 3.3 ex-US) & 4.8 US non-rheums. SLE=3.24 & 12.3 for US non-Rheums. FM=1.8 for US rheums & 0.4 vs ex-US Rheums. Rheum Visits Decreased 1982 to 2019 https://t.co/5ugk34MJ3b https://t.co/NDMYZT7pil

Links:

Dr. John Cush RheumNow ( View Tweet)
Toxic Epiderman Necrolysis vs Acute Cutaneous Lupus Erythematosus https://t.co/wKX3v01RUb https://t.co/SWwnH7ph04

Links:

Dr. John Cush RheumNow ( View Tweet)
Specific ACPAs and Autoantibodies Lead to RA-Associated ILD https://t.co/KLq3CYc20P https://t.co/G7u36CWOTn

Links:

Dr. John Cush RheumNow ( View Tweet)
EHR study of UK Clinical Practice Research Datalink studied 318 hospitalized gout pts showing there is a 30d increased risk of VTE after gout flare aIRR 2.31 (1.39-3.82), that disappeared 31-90d after. https://t.co/h2v8KbiSwX https://t.co/gsfnR50gTD

Links:

Dr. John Cush RheumNow ( View Tweet)
Vision Loss with ANCA-Associated Vasculitis Shelley K. Dhillon, MD, presents her poster at RWCS 2023. https://t.co/e25SFDXk7O https://t.co/J1AsdE3b0Y

Links:

Dr. John Cush RheumNow ( View Tweet)
Danish Pop. study of frequency of TMJ and oro-facial Dz in 613 pts w/ #JIA followed 4 yrs. Cumulative incidence of TMJ dz was 30%; 21% had arthritis-induced dentofacial deformity & dentofacial dysfunction (52%). TMJ predicted by younger onset, F, ANA+ https://t.co/M39q3snO3n https://t.co/ajPz27lmvt

Links:

Dr. John Cush RheumNow ( View Tweet)
Tigulixostat is a non-purine xanthine oxidase inhibitor studied in 143 gout pts vs PBO with goal of SUA < 5. TIG was effective at 50mg (47%), 100 mg (45% ), 200 mg (62%) vs PBO 2.6% at week 12; w/ more gout flares in PBO Rx pts (13% vs 9%) https://t.co/d9lAjCBUmZ https://t.co/BERW51HW2B

Links:

Dr. John Cush RheumNow ( View Tweet)
PR3 autoreactive CD4+T cells found in affected kidneys of 72 pts with PR3+ ANCA assoc vasculitis. These cytotoxic GPR56+CD4+T cells were significantly greater in those with inactive (vs active GPA), suggesting they may be affected by immunosuppression https://t.co/dHFhgnB8yE https://t.co/ZxV6INeCrU

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×